|
Brain Neoplasms
|
0.500 |
CausalMutation
|
group |
CGI |
|
|
|
|
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Patients with wild-type IDH1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH1 tumors and no podoplanin expression (6-month risk 18.2% vs. 0%).
|
29676036 |
2018 |
|
Brain Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used human glioma tissues and derived brain tumor stem cells (BTSCs) to study the expression of HIF1α target genes in IDH mutant ((mt)) and IDH wild-type ((wt)) tumors.
|
24366912 |
2014 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Isocitrate Dehydrogenase-1 (<i>IDH1)</i> is a driver gene in several cancers including brain tumors such as low-grade and high-grade gliomas.
|
29971034 |
2018 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown.
|
19359588 |
2009 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquisition scheme that uses an ultrahigh magnetic field (≥ 7T) capable of noninvasively detecting 2-HG with quantitative measurements sufficient to differentiate mutant cytosolic IDH1 and mitochondrial IDH2 in human brain tumors.
|
26669865 |
2016 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We also used targeted genotyping to examine the role of tumor-related genes in brain tumor development and specifically examined the clinical consequences of MAE at TP53 and IDH1.
|
22144470 |
2012 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
There is growing interest in identification of diagnostic, prognostic or predictive blood biomarkers in CNS tumor patients, and emerging studies indicate that certain brain tumors are indeed associated with distinct profiles of circulating factors such as proteins (e.g., glial fibrillary acidic protein), DNA fragments (e.g., containing mutated IDH) or miRNAs (e.g., miRNA-21).
|
23547822 |
2013 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours.
|
23414134 |
2013 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Exon 4 of IDH1 and IDH2 was analyzed in a series of brain tumors classified according to current WHO criteria.
|
29535392 |
2018 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |
|
Brain Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
|
18985363 |
2008 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We first demonstrated identical IDH mutations in the brain tumor samples from various locations in this patient, but different 1p,19q results by fluorescent in-situ hybridization, different whole genome copy number profiles by OncoScan analysis, and a discrepant IDH2M131I mutation unique to one tumor, supporting a multifocal disease process in the setting of somatic IDH mosaicism.
|
30159860 |
2018 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified in a number of cancer types, including brain cancer.
|
29849122 |
2018 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We show that compound 5 exhibits good brain exposure and potent 2-HG inhibition in a HT1080-derived mouse xenograft model, which makes it a potential preclinical candidate to treat IDH1-mutant brain tumors.
|
31561044 |
2019 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
|
23558169 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquired somatic mutations of IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases.
|
22397365 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Metrics used for this range from quantification of single oncometabolites (such as 2-hydroxyglutarate in mutant IDH1 glial brain tumours) to selected metabolite ratios (such as total choline to N-acetylaspartate (plain ratio or CNI index)) or the whole <sup>1</sup> H MRSI(I) pattern through pattern recognition analysis.
|
30633389 |
2019 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cytosolic isocitrate dehydrogenase 1 (IDH1) with an R132H mutation in brain tumors loses its enzymatic activity for catalyzing isocitrate to α-ketoglutarate (α-KG) and acquires new activity whereby it converts α-KG to 2-hydroxyglutarate.
|
24077277 |
2013 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1).
|
27820599 |
2016 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We investigated IDH1 mutations in a series of 134 brain tumors to determine the prevalence and prognostic impact of IDH1 mutations.
|
22922798 |
2012 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Other than brain tumor or hematologic malignancies, intrahepatic cholangiocarcinoma (iCC) is a well-known solid tumor with IDH1 mutation (6.8-20%).
|
28403884 |
2017 |
|
Brain Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors.
|
27655638 |
2016 |